15 results on '"Jabra Zarka"'
Search Results
2. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
- Author
-
Ghayas C. Issa, Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning, Nicholas J. Short, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Branko Cuglievan, Naval Daver, Courtney D. DiNardo, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero, Marina Konopleva, Michael Andreeff, Hagop M. Kantarjian, and Farhad Ravandi
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 without significant impact on prognosis, except for patients with ≥2 mutations with lower overall survival (OS). KMT2Ar AML had worse outcomes compared with diploid AML when newly diagnosed and at relapse, especially following second salvage (median OS of 2.4 vs 4.8 months, P
- Published
- 2021
- Full Text
- View/download PDF
3. Patient characteristics predicting prolonged length of hospital stay following robotic-assisted radical prostatectomy
- Author
-
Albert El Hajj, Muhieddine Labban, Guillaume Ploussard, Jabra Zarka, Nassib Abou Heidar, Aurelie Mailhac, and Hani Tamim
- Subjects
Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Objective: The objective of this study is to determine the preoperative patient characteristics predicting prolonged length of hospital stay (pLOS) following robotic-assisted radical prostatectomy (RARP). Methods: The National Surgical Quality Improvement Program (NSQIP) database was used to select patients who underwent RARP without other concomitant surgeries between 2008 and 2016. Patients’ demographics, comorbidities, and laboratory markers were collected to evaluate their role in predicting pLOS. The pLOS was defined as length of stay (LOS) >2 days. A multinomial logistic regression was constructed adjusting for postoperative surgical complications to assess for the predictors of pLOS. Results: We obtained data for 31,253 patients of which 20,774 (66.5%) patients stayed ⩽1 day, 6993 (22.4%) patients stayed for 2 days, and 3486 (11.2%) patients stayed for >2 days. Demographic variables – including body mass index (BMI)
- Published
- 2022
- Full Text
- View/download PDF
4. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia
- Author
-
Iman Abou Dalle, Ronald Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li, Jing Ning, Nicholas J. Short, Maro Ohanian, Jorge E. Cortes, Elias J. Jabbour, and Ghayas C. Issa
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Treatment of acute leukemia with intensive chemotherapy leads to an increased risk of myelosuppression. Luteinizing hormone (LH) blockade improves hematopoietic recovery in mice after radiation or chemotherapy, through protection of the hematopoietic stem cells which express the LH receptor. We hypothesized that LH blockade improves hematopoietic recovery following intensive chemotherapy in patients with leukemia. We conducted a retrospective analysis on pre-menopausal women with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) who received intensive chemotherapy and leuprolide given for abnormal uterine bleeding prevention or treatment. Given that leuprolide was more commonly administered in younger patients, we performed propensity score matching between the leuprolide (AML N=64; ALL N=49) and control groups (AML N=128; ALL N=98 patients). Patients with AML who received leuprolide had an additional increase of 13.8 x 109/L/year in their platelet count, and a 0.19 x 109/L/year increase in their lymphocyte count after chemotherapy compared to control (P=0.02; P=0.03 respectively). Those with ALL who received leuprolide had an additional increase of 0.37 x 109/L/year in their absolute neutrophil count (P=0.02). In AML, leuprolide was associated with higher long-term hemoglobin levels (P
- Published
- 2020
- Full Text
- View/download PDF
5. Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
- Author
-
Ghayas C. Issa, Aram Bidikian, Edward Ayoub, Feng Wang, Vakul Mohanty, Jake Leighton, Xiaogang Wu, Tallie Patsilevas, Zoe Alaniz, Jabra Zarka, Rashmi Kanagal-Shamanna, Naval Daver, Andy Futreal, Marina Konopleva, Nicholas Navin, Jianhua Zhang, Ken Chen, and Michael Andreeff
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
6. A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
- Author
-
Aram Bidikian, Sreyashi Basu, He Zhong, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, and Ghayas C. Issa
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
7. Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
- Author
-
Ghayas C. Issa, Vakul Mohanty, Edward Ayoub, Feng Wang, Jake Leighton, Xiaogang Wu, Aram Bidikian, Tallie Patsilevas, Zoe Alaniz, Jabra Zarka, Rashmi Kanagal-Shamanna, Andy Futreal, Naval Daver, Marina Konopleva, Nicholas Navin, Jianhua Zhang, Ken Chen, and Michael Andreeff
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
8. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
- Author
-
Naval Daver, Jing Ning, Guillermo Garcia-Manero, Tapan M. Kadia, Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Daewoo Pak, Jabra Zarka, Farhad Ravandi, Marina Konopleva, Fadi Haddad, Zhenya Tang, Keyur P. Patel, Ghayas C. Issa, Elias Jabbour, Gautam Borthakur, Courtney D. DiNardo, Branko Cuglievan, Koji Sasaki, and Michael Andreeff
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Methyltransferase ,Multivariate analysis ,Adolescent ,Adverse outcomes ,Chromosomal translocation ,Article ,Young Adult ,Internal medicine ,hemic and lymphatic diseases ,medicine ,Humans ,Transplantation, Homologous ,Leukaemia ,RC254-282 ,Aged ,Retrospective Studies ,Aged, 80 and over ,Gene Rearrangement ,Adult patients ,biology ,business.industry ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Hematology ,Histone-Lysine N-Methyltransferase ,Middle Aged ,Prognosis ,Survival Analysis ,Leukemia, Myeloid, Acute ,KMT2A ,Mutation ,biology.protein ,Female ,Allogeneic hematopoietic stem cell transplant ,business ,Myeloid-Lymphoid Leukemia Protein - Abstract
Acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) has adverse outcomes. However, reports on the prognostic impact of various translocations causing KMT2Ar are conflicting. Less is known about associated mutations and their prognostic impact. In a retrospective analysis, we identified 172 adult patients with KMT2Ar AML and compared them to 522 age-matched patients with diploid AML. KMT2Ar AML had fewer mutations, most commonly affecting RAS and FLT3 without significant impact on prognosis, except for patients with ≥2 mutations with lower overall survival (OS). KMT2Ar AML had worse outcomes compared with diploid AML when newly diagnosed and at relapse, especially following second salvage (median OS of 2.4 vs 4.8 months, P KMT2Ar AML (t-AML) had worse outcomes compared with de novo KMT2Ar AML (median OS of 0.7 years vs 1.4 years, P P KMT2Ar did not predict survival, unlike age and allo-HSCT. In conclusion, KMT2Ar was associated with adverse outcomes regardless of translocation subtype. Therefore, AML risk stratification guidelines should include all KMT2Ar as adverse.
- Published
- 2021
9. Prevalence and Risk Factors for Bleeding in Individuals with Hereditary Hemorrhagic Telangiectasia: A National Inpatient Sample Study
- Author
-
Jabra Zarka, Kwonho Jeong, Jonathan G. Yabes, and Margaret V. Ragni
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
10. Calibration-free NGS quantitation of mutations below 0.01% VAF
- Author
-
Pengying Hao, Michael Xiangjiang Wang, Sherry Xi Chen, Weijie Yao, Jinny X. Zhang, David Zhang, Ghayas C. Issa, Jabra Zarka, Lucia Ruojia Wu, Lauren Yuxuan Cheng, Lawrence N. Kwong, and Peng Dai
- Subjects
Neoplasm, Residual ,Science ,General Physics and Astronomy ,Computational biology ,Biology ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,Deep sequencing ,Article ,medicine ,Humans ,In patient ,Indel ,Gene ,Melanoma ,Mutation ,Multidisciplinary ,Myeloid leukemia ,High-Throughput Nucleotide Sequencing ,General Chemistry ,Minimal residual disease ,Leukemia, Myeloid, Acute ,Calibration ,Next-generation sequencing ,Calibration free - Abstract
Quantitation of rare somatic mutations is essential for basic research and translational clinical applications including minimal residual disease (MRD) detection. Though unique molecular identifier (UMI) has suppressed errors for rare mutation detection, the sequencing depth requirement is high. Here, we present Quantitative Blocker Displacement Amplification (QBDA) which integrates sequence-selective variant enrichment into UMI quantitation for accurate quantitation of mutations below 0.01% VAF at only 23,000X depth. Using a panel of 20 genes recurrently altered in acute myeloid leukemia, we demonstrate quantitation of various mutations including single base substitutions and indels down to 0.001% VAF at a single locus with less than 4 million sequencing reads, allowing sensitive MRD detection in patients during complete remission. In a pan-cancer panel and a melanoma hotspot panel, we detect mutations down to 0.1% VAF using only 1 million reads. QBDA provides a convenient and versatile method for sensitive mutation quantitation using low-depth sequencing., Quantification of rare somatic mutations is essential for basic research and translational applications. Here the authors present Quantitative Blocker Displacement Amplification allowing for accurate detection of mutations below 0.01% VAF.
- Published
- 2021
11. Patient characteristics predicting prolonged length of hospital stay following robotic-assisted radical prostatectomy
- Author
-
Albert El Hajj, Muhieddine Labban, Guillaume Ploussard, Jabra Zarka, Nassib Abou Heidar, Aurelie Mailhac, and Hani Tamim
- Subjects
Urology - Abstract
Objective: The objective of this study is to determine the preoperative patient characteristics predicting prolonged length of hospital stay (pLOS) following robotic-assisted radical prostatectomy (RARP). Methods: The National Surgical Quality Improvement Program (NSQIP) database was used to select patients who underwent RARP without other concomitant surgeries between 2008 and 2016. Patients’ demographics, comorbidities, and laboratory markers were collected to evaluate their role in predicting pLOS. The pLOS was defined as length of stay (LOS) >2 days. A multinomial logistic regression was constructed adjusting for postoperative surgical complications to assess for the predictors of pLOS. Results: We obtained data for 31,253 patients of which 20,774 (66.5%) patients stayed ⩽1 day, 6993 (22.4%) patients stayed for 2 days, and 3486 (11.2%) patients stayed for >2 days. Demographic variables – including body mass index (BMI) Conclusion: Preoperative patient characteristics and comorbidities can predict pLOS. These findings can be used preoperatively for risk assessment and patient counseling.
- Published
- 2021
12. Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
- Author
-
Ghayas C. Issa, Nicholas J. Short, Jabra Zarka, and Rashmi Kanagal-Shamanna
- Subjects
0301 basic medicine ,NPM1 ,Cytoplasm ,lcsh:QH426-470 ,Ribosome biogenesis ,Review ,Biology ,03 medical and health sciences ,0302 clinical medicine ,AML ,hemic and lymphatic diseases ,Gene expression ,Genetics ,medicine ,Humans ,Genetic Predisposition to Disease ,Gene ,Genetics (clinical) ,Nucleophosmin ,Myeloid leukemia ,Nuclear Proteins ,nucleophosmin (NPM1) ,medicine.disease ,targeted therapies ,Leukemia ,Leukemia, Myeloid, Acute ,lcsh:Genetics ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,gene expression ,ADP-Ribosylation Factor 1 ,Bone marrow ,Tumor Suppressor Protein p53 - Abstract
Nucleophosmin (NPM1) is a ubiquitously expressed nucleolar protein involved in ribosome biogenesis, the maintenance of genomic integrity and the regulation of the ARF-p53 tumor-suppressor pathway among multiple other functions. Mutations in the corresponding gene cause a cytoplasmic dislocation of the NPM1 protein. These mutations are unique to acute myeloid leukemia (AML), a disease characterized by clonal expansion, impaired differentiation and the proliferation of myeloid cells in the bone marrow. Despite our improved understanding of NPM1 mutations and their consequences, the underlying leukemia pathogenesis is still unclear. Recent studies that focused on dysregulated gene expression in AML with mutated NPM1 have shed more light into these mechanisms. In this article, we review the current evidence on normal functions of NPM1 and aberrant functioning in AML, and highlight investigational strategies targeting these mutations.
- Published
- 2020
13. Coronavirus Goes Viral: Quantifying the COVID-19 Misinformation Epidemic on Twitter
- Author
-
Cindy Traboulsi, Elio Adib, Basil S. Karam, Elie W. Akl, Joseph Abi Jaoude, Afif Kraitem, Jabra Zarka, Ramez Kouzy, Khalil Baddour, and Molly B. El Alam
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,social media ,Psychological intervention ,coronavirus ,Infectious Disease ,030204 cardiovascular system & hematology ,epidemic ,03 medical and health sciences ,0302 clinical medicine ,infodemic ,Pandemic ,Health care ,medicine ,Social media ,Misinformation ,Descriptive statistics ,business.industry ,Public health ,pandemic ,public health ,General Engineering ,Advertising ,covid-19 ,Epidemiology/Public Health ,twitter ,business ,030217 neurology & neurosurgery - Abstract
Background Since the beginning of the coronavirus disease 2019 (COVID-19) epidemic, misinformation has been spreading uninhibited over traditional and social media at a rapid pace. We sought to analyze the magnitude of misinformation that is being spread on Twitter (Twitter, Inc., San Francisco, CA) regarding the coronavirus epidemic. Materials and methods We conducted a search on Twitter using 14 different trending hashtags and keywords related to the COVID-19 epidemic. We then summarized and assessed individual tweets for misinformation in comparison to verified and peer-reviewed resources. Descriptive statistics were used to compare terms and hashtags, and to identify individual tweets and account characteristics. Results The study included 673 tweets. Most tweets were posted by informal individuals/groups (66%), and 129 (19.2%) belonged to verified Twitter accounts. The majority of included tweets contained serious content (91.2%); 548 tweets (81.4%) included genuine information pertaining to the COVID-19 epidemic. Around 70% of the tweets tackled medical/public health information, while the others were pertaining to sociopolitical and financial factors. In total, 153 tweets (24.8%) included misinformation, and 107 (17.4%) included unverifiable information regarding the COVID-19 epidemic. The rate of misinformation was higher among informal individual/group accounts (33.8%, p
- Published
- 2020
14. AML-318: Predictors of Outcomes in AML with MLL Rearrangement
- Author
-
Nicholas J. Short, Elias Jabbour, Ghayas C. Issa, Hagop M. Kantarjian, Jabra Zarka, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Tapan M. Kadia, and Koji Sasaki
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Adult patients ,business.industry ,Context (language use) ,Hematology ,Mll rearrangement ,Newly diagnosed ,Tertiary care ,Immunophenotyping ,MIXED LINEAGE LEUKEMIA ,hemic and lymphatic diseases ,Internal medicine ,Retrospective analysis ,medicine ,business ,neoplasms - Abstract
Context Outcomes and determinants of response in AML with rearrangements of the Mixed Lineage Leukemia (MLL) gene are unknown. Objectives To determine the mutational, phenotypic, and clinical characteristics of MLLr AML. Design A retrospective analysis including adult patients with newly diagnosed MLLr AML at MD Anderson from 1990–2019. Setting Tertiary care center. Patients One hundred seventy-four patients with newly diagnosed MLLr AML were analyzed and compared to 522 age-matched patients with a diploid karyotype (Dp). Main Outcomes Measures Mutational and immunophenotypic profiles, in addition to responses and survival outcomes. Results MLLr patients were younger (median age: 51 vs 61 years for Dp, P Conclusions MLLr AML has unique molecular and phenotypic features and is associated with dismal outcomes improved only with HSCT. Given the limited progress made in treatment of this entity, novel approaches are needed.
- Published
- 2020
- Full Text
- View/download PDF
15. P033 Cytomegalovirus colitis: Does concomitant inflammatory bowel disease lead to worse clinical outcomes? Descriptive study from a single-centre experience
- Author
-
Jana, Hashash, primary, David, Binion, additional, Afif, Kraitem, additional, Mohamad, Hosni, additional, Jabra, Zarka, additional, Ramez, Kouzi, additional, and Zeina, Kanafani, additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.